Abstract 1182P
Background
We previously validated a clinical risk classification model for resected SqCLC by combining clinicopathological predictors to discriminate patients' (pts) prognosis (Pilotto JTO 2015). Here we investigate the molecular portrait of prognostic outliers to identify differentially expressed, potentially druggable molecular targets (AIRCMFAG project no. 14282).
Methods
On the basis of the published 3-class model, 176 and 46 pts with good and poor prognosis, respectively, were identified. Next Generation Sequencing (NGS) analysis (Ion Proton system, Ion Ampliseq custom panel) evaluating Somatic Mutations (SM) and Copy Number Alternations (CNA) of 44 genes was performed; RNA expression, immunohistochemistry (IHC), immunofluorescence (FISH) were performed on Tissue Micro-Arrays (TMA). Descriptive statistics was adopted; continuous variables were dichotomized according to AUC or medians.
Results
The distribution of relevant SM and CNA analysis of 60 pts according to prognosis (good: 27; poor: 33) is reported in the table.
| Analysis (NGS) | Gene | Good: 27 pts [%] | Poor: 33 pts [%] | p-value |
|---|---|---|---|---|
| SM | PI3KCA | 0 | 3 [9.1] | 0.24 |
| NOTCH1 | 2 [7.4] | 0 | 0.19 | |
| CUL3 | 2 [7.4] | 0 | 0.19 | |
| DDR2 | 3 [11.1] | 0 | 0.085 | |
| CDH10 | 4 [14.8] | 1 [3.0] | 0.16 | |
| CDH1 | 3 [11.1] | 1 [3.0] | 0.3 | |
| CNA Gains | RICTOR | 1 [3.7] | 9 [27.3] | 0.017 |
| SOX2 | 20 [74.1] | 17 [51.5] | 0.11 | |
| CNA Losses | CDKN2A | 6 [22.2] | 1 [3.0] | 0.038 |
| PTEN | 11 [40.7] | 17 [51.5] | 0.57 | |
| RB1 | 8 [29.6] | 17 [51.5] | 0.12 | |
| SMAD4 | 9 [33.3] | 19 [57.6] | 0.074 |
No significant differences in terms of phospho-mTOR and PD-L1 IHC expression were found in the 2 different prognostic subgroups. Patients with concurrent high PD1, SNAI, and Vimentin RNA expression were significantly more likely to be at poor prognosis (p = 0.003).
Conclusions
Although performed on a limited number of pts, the approach to comprehensively analyze DNA, RNA and proteins, using different methodologies, strengthens the clinically relevance of RICTOR/PI3K/mTOR signaling cascade activation in determining the poor prognosis of SqCLC. The possibility to inhibit this pathway with selective agents is currently under investigation in in vitro preclinical models.
Clinical trial identification
Legal entity responsible for the study
University of Verona, Verona, Italy
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC): MFAG Project 14282.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract